Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303201 | 0.94 | SIGMAR1 (0.43) | OPRM1OPRD1OPRK1DRD2SIGMAR1 | |
| SCHEMBL8303556 | 0.93 | SIGMAR1 (0.43) | OPRM1OPRD1OPRK1DRD2SIGMAR1 | |
| SCHEMBL8306497 | 0.89 | SIGMAR1 (0.42) | OPRM1OPRD1OPRK1SIGMAR1CCR3 | |
| SCHEMBL8304636 | 0.83 | OPRM1 (0.41) | OPRM1OPRD1OPRK1DRD2CCR3 | |
| SCHEMBL8303444 | 0.82 | SIGMAR1 (0.55) | DRD2SIGMAR1CCR3 | |
| SCHEMBL8307036 | 0.80 | HRH3 (0.51) | SIGMAR1CCR3HTR1A | |
| SCHEMBL9143193 | 0.79 | DRD2 (0.39) | DRD2CCR3HTR1A | |
| SCHEMBL8303188 | 0.78 | HTR2B (0.33) | DRD2SIGMAR1CCR3HTR1AMAPT | |
| SCHEMBL8304291 | 0.77 | SIGMAR1 (0.46) | SIGMAR1HTR1AMAPT | |
| SCHEMBL9178363 | 0.76 | SIGMAR1 (0.41) | DRD2SIGMAR1CCR3HTR1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0574313-B1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR (FR) | 1999-10-06 | — | — | EP | claimed |
| US-5464834-A | Antidepressants, central nervous system | ADIR ET COMPAGNIE (FR) | 1995-11-07 | — | — | US | claimed |
| EP-0574313-A1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-12-15 | — | — | EP | claimed |
| EP-0574313-B1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR (FR) | 1999-10-06 | — | — | EP | disclosed |
| US-5464834-A | Antidepressants, central nervous system | ADIR ET COMPAGNIE (FR) | 1995-11-07 | — | — | US | disclosed |
| EP-0574313-A1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-12-15 | — | — | EP | disclosed |